Please assess the completion status of the following clinical trial:

Trial Title: An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participated in United Therapeutics Study TDE-PH-310~* All women of childbearing potential (WOCBP) must have practiced true abstinence from intercourse when it was in line with their preferred and usual lifestyle or used 2 different forms of highly effective contraception for the duration of the study and for at least 30 days after discontinuing study medication.~* Males who participated in the study must have used a condom during the length of the study and for at least 48 hours after their last dose of study medication.~Exclusion Criteria:~* The subject was pregnant or lactating.~* The subject had received infused or inhaled prostacyclin therapy for 29 days or more.~* The subject was prematurely discontinued from TDE-PH-310 for reasons other than a clinical worsening event.~* The subject developed a concurrent illness or condition during the conduct of TDE-PH-310 which, in the opinion of the Investigator, would represent a risk to their overall health if they enrolled in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- UT-15C (Type: EXPERIMENTAL): Open label access

Based on this trial design, predict the completion outcome and termination type (if applicable).